This study is for adults with a type of cancer called metastatic leiomyosarcoma (LMS), which means the cancer has spread to other parts of the body. Researchers are testing if a new drug combination, **Lurbinectedin plus Doxorubicin**, helps patients live longer without the cancer getting worse, compared to using just **Doxorubicin**. Doxorubicin is a medicine already used for some cancers. The study is in two phases: **Phase IIb/III** means they are checking safety and effectiveness. Participants must be 18 or older and haven't had certain treatments before. You cannot join if you have certain heart or liver diseases, or if you're pregnant. Participants will have regular check-ups and treatments over time. The study takes several weeks, and you might experience side effects. It's important to discuss with your doctor if this study is right for you.
- Study Length: Requires regular visits and treatments over weeks.
- Eligibility: Must be 18+, with specific health criteria.
- Compensation/Risks: Potential side effects; discuss with a doctor.